Effects Of ID Ara-C And MA In Patients With Refractory Or Relapsed Acute Myeloid Leukemia

Objective: To investigate effects of ID Ara-C and MA in patients with refractory or relapsed acute myeloid leukemia (AML).Methods: 44 adult patients with refractory or relapsed AML(except M3) who received ID Ara-C contained regimen or MA regimen as study objects were retrospectively analyzed from January 2005 to December 2010 in our hospital. Among of them, 28 patients were treated by ID Ara-C contained regimen, while 16 patients received MA regimen.Results: 17(38.6%) patients obtained CR, and 4(9.1%) were PR. 21 patients responded overall. ORR was 47.7%. The rate of CR and OR of ID Ara-C contained regimen was 35.7% and 42.8% respectively. The rate of CR and OR of MA regimen was 43.8% and 56.2% respectively. No statistical significance was found in the rate of CR and OR that were in ID Ara-C and MA regimen(P>0.05). The chief adverse reactions of these chemotherapy regimens were bone marrow supression and gastrointestinal side effects. Compared to MA regimen, gastrointestinal side effects of ID Ara-C contained regimen was more severe, the difference between two regimen was significant(P<0.05). No statistical significance were found in ID Ara-C contained regimen and MA regimen in other adverse reactions(P>0.05).Conclusion: Both ID Ara-C contained regimen and MA regimen were effective methods for inducing CR in patients with refractory or relapsed AML. The difference of their efficacy was not found. Bone marrow supression and gastrointestinal side effects were the chief adverse reactions. Two regimens were safe and adverse reactions of them were acceptable.